据港交所文件：成都欧林生物科技股份有限公司向港交所提交上市申请书。 ...

Market Overview - The biopharmaceutical sector increased by 0.83% on November 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Biopharmaceutical Sector - Jinke (688670) closed at 25.75, up 19.99% with a trading volume of 92,200 shares [1] - Hualan Biological (301207) closed at 23.33, up 11.25% with a trading volume of 250,500 shares [1] - Saiseng Pharmaceutical (300485) closed at 11.95, up 5.19% with a trading volume of 168,000 shares [1] - Other notable gainers include Bohui Innovation (300318) at 6.84 (+3.32%) and Dongbao Biological (300239) at 5.72 (+3.25%) [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 40.88 million yuan from institutional investors, while retail investors experienced a net outflow of 147 million yuan [2] - The sector's overall capital flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Capital Flow - Jinke (688670) had a net inflow of 39.66 million yuan from institutional investors, while retail investors showed a net outflow of 13.72 million yuan [3] - Other stocks like Watson Bio (300142) and Hualan Bio (002007) also experienced significant net inflows from institutional investors, indicating positive sentiment [3] - Conversely, stocks like Dongbao Biological (300239) and Bohui Innovation (300318) faced net outflows from retail investors, suggesting mixed investor sentiment [3]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Chengdu Olymvax Biopharmaceuticals Inc. 成都歐林生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「委員 會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，當中所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向成都歐林生物科技股份有限公司（「本公司」，及其附屬公司統稱 為「本集團」）、其獨家保薦人、整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記 前，本公司不會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀 請，有意投資者務請僅依據向香港公司註冊處處長登記的本公司招股章程作出投資決定。招股 ...

Core Viewpoint - Oulin Biotech experienced a decline of 5.66% in stock price on November 21, with a trading volume of 95.67 million yuan, indicating potential market volatility and investor sentiment concerns [1]. Financing Summary - On November 21, Oulin Biotech had a financing buy-in amount of 7.32 million yuan and a financing repayment of 11.86 million yuan, resulting in a net financing outflow of 4.54 million yuan [1]. - The total financing and securities balance for Oulin Biotech reached 326 million yuan, accounting for 3.74% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - The company had no short selling activity on November 21, with a short selling balance of 0 yuan, also reflecting a high percentile compared to the past year [1]. Company Performance - As of September 30, Oulin Biotech reported a total of 10,200 shareholders, an increase of 56.42% from the previous period, while the average circulating shares per person decreased by 36.07% to 39,746 shares [2]. - For the period from January to September 2025, Oulin Biotech achieved a revenue of 507 million yuan, representing a year-on-year growth of 31.11%, and a net profit attributable to shareholders of 47.48 million yuan, showing a significant increase of 1079.36% [2]. Dividend and Shareholding Structure - Since its A-share listing, Oulin Biotech has distributed a total of 15.43 million yuan in dividends [3]. - As of September 30, 2025, among the top ten circulating shareholders, the fund "Xingquan Helun Mixed A" held 15.44 million shares, remaining unchanged from the previous period, while "Xingquan Heyi Mixed A" held 8.92 million shares, also unchanged [3]. - A new shareholder, "Xingquan Commercial Model Mixed (LOF) A," entered the top ten with a holding of 4.64 million shares [3].

投资者可于 2025 年 11 月 24 日(星期一)至 11 月 28 日(星期五)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@olymvax.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 证券代码：688319 证券简称：欧林生物 公告编号：2025-064 成都欧林生物科技股份有限公司关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 成都欧林生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年前三季度的经营成果、财务状况，公司计划于 2025 年 12 月 01 日(星期 一)上午 10:00-11:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进 行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年前三季度的经 营成果及财务指标的具体情况 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.94% on November 17, with Kexing Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Bohui Innovation: Closed at 8.00, up 2.56% with a trading volume of 824,300 shares [1] - ST Weiming: Closed at 8.31, up 2.21% with a trading volume of 60,800 shares [1] - Major decliners included: - Kexing Pharmaceutical: Closed at 34.59, down 7.88% with a trading volume of 53,300 shares [2] - Jinwei: Closed at 26.05, down 7.06% with a trading volume of 123,100 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 1.211 billion yuan from institutional investors, while retail investors contributed a net inflow of 893 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Wanzhe Co.: Net outflow of 37.20 million yuan from institutional investors [3] - Olin Bio: Net inflow of 13.81 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different companies within the sector [3]

Core Insights - On November 14, Oulin Bio's stock rose by 4.29%, with a trading volume of 271 million yuan [1] - The company reported a net financing outflow of 913,200 yuan on the same day, with a total financing and securities balance of 331 million yuan [1] - Oulin Bio's main business involves the research, production, and sales of human vaccines, with significant revenue contributions from various vaccine products [1] Financing and Trading Data - On November 14, Oulin Bio had a financing buy-in of 31.69 million yuan, while the financing balance reached 331 million yuan, accounting for 3.29% of the circulating market value [1] - The financing balance is above the 90th percentile level over the past year, indicating a high level of financing activity [1] - No shares were sold or repaid in the securities lending market on the same day, with a balance of 0 yuan [1] Financial Performance - As of September 30, Oulin Bio reported a total revenue of 507 million yuan for the first nine months of 2025, representing a year-on-year growth of 31.11% [2] - The net profit attributable to shareholders reached 47.48 million yuan, showing a significant increase of 1079.36% compared to the previous period [2] Shareholder and Dividend Information - Since its A-share listing, Oulin Bio has distributed a total of 15.43 million yuan in dividends [3] - As of September 30, 2025, the number of shareholders increased to 10,200, a rise of 56.42%, while the average circulating shares per person decreased by 36.07% to 39,746 shares [2][3] - Notable institutional holdings include XQH Run Mixed A and XQH Yi Mixed A, with stable shareholding numbers [3]

证券代码：688319 证券简称：欧林生物 公告编号：2025-063 一、通知债权人的原由 成都欧林生物科技股份有限公司（以下简称"公司"或"欧林生物"）于 2025 年 10 月 28 日召开第七届董事会第五次会议，并于 2025 年 11 月 14 日召开 2025 年第二次临时股东会，审议通过了《关于回购注销 2023 年限制性股票激励计划首 次授予部分已获授尚未解除限售的第一类限制性股票的议案》，具体内容详见公 司于 2025 年 10 月 30 日在上海证券交易所网站（www.sse.com.cn）披露的《成都 欧林生物科技股份有限公司关于回购注销2023年限制性股票激励计划首次授予部 分已获授尚未解除限售的第一类限制性股票的公告》（公告编号：2025-055）。 根据《上市公司股权激励管理办法》等法律法规及公司《2023 年限制性股票 激励计划（草案）》（以下简称"《激励计划（草案）》"、"本激励计划"）、 《2023 年限制性股票激励计划实施考核管理办法》（以下简称"《考核管理办法》"） 的相关规定，鉴于本激励计划首次授予第二个解除限售期公司层面业绩未达到《激 励计划（草案）》和《考核管理办法 ...

北京德恒（成都）律师事务所 关于成都欧林生物科技股份有限公司 2025 年第二次临时股东会的 法律意见 四川省成都市高新区天府大道中段 666 号希顿国际广场 B 座 20 层 电话：028-83338385 传真：028-83338385 邮编：610041 北京德恒（成都）律师事务所 关于成都欧林生物科技股份有限公司 2025年第二次临时股东会的法律意见 北京德恒（成都）律师事务所 关于成都欧林生物科技股份有限公司 2025 年第二次临时股东会的法律意见 京德成律法意字（2025）第 110240 号 致：成都欧林生物科技股份有限公司 成都欧林生物科技股份有限公司（以下简称"公司"）2025 年第二次临时 股东会（以下简称"本次会议"）于 2025 年 11 月 14 日召开。北京德恒（成都） 律师事务所（以下简称"德恒"）受公司委托，指派律师（以下简称"德恒律师"） 出席了本次会议，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委 员会《上市公司股东会规则（2025 年修订）》（以下简称"《股东会规则》"）、 《成都欧林生 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-062 成都欧林生物科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 80 | | --- | --- | | 普通股股东人数 | 80 | | 2、出席会议的股东所持有的表决权数量 | 162,204,483 | | 普通股股东所持有表决权数量 | 162,204,483 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 39.9583 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 39.9583 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长樊绍文先生主持，会议采用现场投票 （ ...